Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Adipose Derived Stem Cell Therapy for Autism

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2011 by Ageless Regenerative Institute.
Recruitment status was:  Not yet recruiting
Instituto de Medicina Regenerativa, S.A. de C.V.
Information provided by (Responsible Party):
Ageless Regenerative Institute Identifier:
First received: December 27, 2011
Last updated: March 19, 2014
Last verified: December 2011

The intent of this clinical study is to answer the questions:

  1. Is the proposed treatment safe
  2. Is treatment effective in improving the disease pathology of patients with Autism.

Condition Intervention Phase
Procedure: Fat Harvesting and Stem Cell Injection
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Autism

Further study details as provided by Ageless Regenerative Institute:

Primary Outcome Measures:
  • Improvement in the Childhood Autism Rating Scale,CARS [ Time Frame: 3 months ]
  • Improvement in the Clinical Global Impression Scale, CGI [ Time Frame: 3 months ]
  • Improvement in the Childhood Autism Rating Scale,CARS [ Time Frame: 6 months ]
  • Improvement in the Clinical Global Impression Scale, CGI [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Improvement in the Aberrant Behavior Checklist, ABC [ Time Frame: 3 months ]
  • Improvement in the Aberrant Behavior Checklist, ABC [ Time Frame: 6 months ]

Estimated Enrollment: 10
Study Start Date: October 2014
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Fat Harvesting and Stem Cell Injection
    Cells will be harvested through a local liposuction and injected via IV delivery
    Other Names:
    • Liposuction
    • Adipose Derived Stem Cell Injection
    • ADSC
    • Lipo
    • Fat Stem Cells
    • IV
Detailed Description:
This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation after liposuction using an IV delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered intravenously.

Ages Eligible for Study:   3 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children between the ages of 3 and 12 years.
  • DSM-IV diagnosis of Autistic Disorder.
  • Total score of CARS ≥ 30.
  • Parents or legal guardian willing to sign the ICF.

Exclusion Criteria:

  • History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's.
  • History of Epileptic seizure activity in the past 6 months.
  • Autism caused by seizure disorders (active), cerebrovascular disease or brain trauma.
  • The global autism ratings are assessed as being absent, minimal or mild.
  • Existing moderate or severe extrapyramidal symptoms (EPS) or history of tardive dyskinesia.
  • Active infectious disease and/or known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis will have expert consultation to determine eligibility based on the patient's infectious status
  • Enrollment in other trials in the last 3 months without agreement to discontinue them.
  • Life expectancy < 6 months due to concomitant illnesses.
  • Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
  • Patients on chronic immunosuppressive transplant therapy
  • Active clinical infection within one week of enrollment.
  • Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
  • History of cancer
  • Parental unwillingness and/or not able to give written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01502488

Contact: Kristin Comella 813 390 9874

Instituto de Medicina Regenerativa Recruiting
Tijuana, Baja California, Mexico, 22010
Contact: Jesus A Perez         
Principal Investigator: ARNOLDO SIERRA, MD         
Sponsors and Collaborators
Ageless Regenerative Institute
Instituto de Medicina Regenerativa, S.A. de C.V.
Principal Investigator: Arnoldo Sierra, MD Instituto de Medicina Regenerativa
  More Information

Responsible Party: Ageless Regenerative Institute Identifier: NCT01502488     History of Changes
Other Study ID Numbers: ADI-AT-001
Study First Received: December 27, 2011
Last Updated: March 19, 2014

Keywords provided by Ageless Regenerative Institute:
ASC therapy

Additional relevant MeSH terms:
Autistic Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders processed this record on May 25, 2017